Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma

Jérémy H Raymond1,2, Zackie Aktary1,2, Lionel Larue1,2

  • 1Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes, 91400 Orsay, France.

Cancers
|February 15, 2022
PubMed

Insights

G-protein-coupled receptors (GPCRs) are crucial for melanocyte function and pigmentation. Recent research reveals their direct involvement in melanoma development, offering new therapeutic targets.

Area of Science:

  • Cell Biology
  • Dermatology
  • Oncology

Background:

  • G-protein-coupled receptors (GPCRs) are vital for melanocyte homeostasis, regulating pigmentation and skin protection.
  • Established roles in pigmentation contrast with emerging evidence linking GPCRs directly to melanoma.
  • GPCRs signal via heterotrimeric G-proteins, influencing key cellular processes in cancer.

Purpose of the Study:

  • To review GPCR alterations in melanoma.
  • To explore GPCR downstream signaling pathways in melanomagenesis.
  • To discuss preclinical models for evaluating GPCR-targeted melanoma therapies.

Main Methods:

  • Literature review of GPCRs in melanocyte physiology and melanoma.
  • Analysis of GPCR signaling pathways implicated in cancer progression.
  • Evaluation of preclinical models for therapeutic development.

Main Results:

  • GPCRs modulate melanoma proliferation and migration through distinct signaling pathways.
  • Alterations in GPCRs and their signaling are associated with melanoma.
  • Therapeutic strategies targeting GPCRs show promise in preclinical settings.

Conclusions:

  • GPCRs represent a significant factor in melanoma pathogenesis.
  • Understanding GPCR structure and function is key to developing novel melanoma treatments.
  • Targeting GPCRs offers a promising avenue for future melanoma therapies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.0K